E1/E2/E3 Enzyme
E1 activating enzyme; E2 conjugating enzyme; E3 ligating enzyme; Ubiquitin activating enzyme; Ubiquitin conjugating enzyme; Ubiquitin ligase
Ubiquitin (UB) is a protein modifier that regulates many essential cellular processes. To initiate protein modification by UB, the E1 enzyme activates the C-terminal carboxylate of UB to launch its transfer through the E1-E2-E3 cascade onto target proteins. The E1 enzyme is the activating enzyme, to which ubiquitin is attached in an ATP-dependent reaction by a thioester bond. The E2 enzyme is the conjugating enzyme, to which the ubiquitin is transferred from the E1. The E3 is the ubiquitin ligase, which directly or indirectly catalyzes the transfer of the ubiquitin to the target protein (the substrate), with the formation of an isopeptide bond.
All Product Categories
-
E1/E2/E3 Enzyme Inhibitors
(223)
View all products
-
E1/E2/E3 Enzyme Agonists
(6)
View all products
-
E1/E2/E3 Enzyme Antagonist
(1)
View all products
-
E1/E2/E3 Enzyme Activators
(5)
View all products
-
E1/E2/E3 Enzyme Modulators
(9)
View all products
-
E1/E2/E3 Enzyme Inducer
(1)
View all products
-
E1/E2/E3 Enzyme Degraders
(13)
View all products
-
E1/E2/E3 Enzyme Control
(1)
View all products
-
E1/E2/E3 Enzyme Ligands
(15)
View all products
-
Ubiquitin Enzymes Proteins
(116)
View all products
-
E1/E2/E3 Enzyme Related Products (320)
Related Products (320)
-
Recombinant Proteins (116)
-
Antibodies (88)
-
Related Compound Screening Libraries (1)
-
Ubiquitin Conjugating enzyme E2C
0 ImagesCat. No.: HY-E70618Ubiquitin Conjugating enzyme E2C (EC 2.3.2.24) is a member of the E2 ubiquitin-conjugating enzyme family, and it is the principal regulator of pathways for protein degradation in eukaryotes. Ubiquitin Conjugating enzyme E2C is involved in the tumorigenesis of various malignancies. Ubiquitin Conjugating enzyme E2C is also involved in mitotic cyclin disruption, affecting cell cycle progression. Ubiquitin Conjugating enzyme E2C is a prognostic indicator for cholangiocarcinoma.
-
9-cis-UAB30
0 ImagesCat. No.: HY-129108CAS No.: 205252-57-9Synonyms: (9Z)-UAB-309-cis-UAB30 is a rexinoid agonist. 9-cis-UAB30 significantly decreases the proliferation, viability, and motility of both patient-derived xenografts (PDXs). 9-cis-UAB30 induced cell-cycle arrest as demonstrated by the significant increase in the percentage of cells in G1 and a decrease in the percentage of cells in S phase by downregulating SKP2 and/or 20S proteasome activity, which leads to increased p27kip1 protein stability. 9-cis-UAB30 downregulates the abundance of stem cell marker mRNAs (Oct4, Nanog, Sox2, nestin) and upregulates the abundance of differentiation marker mRNAs (β3-tubulin, NSE, HOXC9, GAP43). 9-cis-UAB30 has no adverse effects on the central nervous system and cardiovascular system at the tested dose. 9-cis-UAB30 can be used for the study of neuroblastoma, cutaneous T-cell lymphomas, and breast cancer.
-
SM00465
0 ImagesCat. No.: HY-164133CAS No.: 2983179-22-0SM00465 (Compound 207) is a Cbl-b inhibitor-linker conjugate composed of INT4 (HY-179262) and Linker (HY-179263). SM00465 can be used for ADC synthesis. SM00465 is applicable to the research of immune-related diseases.
-
TRIM21 ligand-1
0 ImagesCat. No.: HY-186250CAS No.: 3055559-33-3
-
(E),(Z)-RNF5 agonist 1
0 ImagesCat. No.: HY-170515ACAS No.: 2231731-82-9(E),(Z)-RNF5 agonist 1 (Compound Analog-1) is a RNF5 agonist that can enhance the ubiquitination and degradation of SARS-CoV-2 E protein by RNF5. (E),(Z)-RNF5 agonist 1 effectively inhibits the replication of SARS-CoV-2 and significantly alleviates pulmonary pathological damage and systemic inflammatory response in mouse infection models. (E),(Z)-RNF5 agonist 1 has a strong cytotoxic effect on neuroblastoma and melanoma. (E),(Z)-RNF5 agonist 1 can be used for research on anti-cancer and anti-viral purposes.
-
Cbl-b-IN-30
0 ImagesCat. No.: HY-179617Cbl-b-IN-30 is an orally active Casitas B-lineage lymphoma-b (CBLB) inhibitor. Cbl-b-IN-30 specifically binds to CBLB and inhibits its E3 ubiquitin ligase activity with an IC50 of 9.1 nM. Cbl-b-IN-30 can promote IL-2 secretion (EC50 = 187.5 nM) and enhance T cell activation. Cbl-b-IN-30 exerts antitumor activity and can induce immune memory. Cbl-b-IN-30 can be used for the research of colon cancer.
-
Anti-RNF43 Antibody
0 ImagesCat. No.: HY-P992297
-
PROTAC BET Degrader-13
0 ImagesCat. No.: HY-175354PROTAC BET Degrader-13 is a BET PROTAC degrader that recruits TRIM21. PROTAC BET Degrader-13 utilizes wild-type TRIM21 to mediate the degradation of PML-eGFP-BRD4 (BD2) fusion protein aggregates, with an EC50 of 1.4 μM in A549 cells expressing TRIM21-FLAG. PROTAC BET Degrader-13 can be used for research on targeted protein degradation and protein aggregate clearance.
-
Cbl-b-IN-29
0 ImagesCat. No.: HY-179575CAS No.: 3070411-10-5Cbl-b-IN-29 is an orally active CBL-B inhibitor. Cbl-b-IN-29 binds to the CBL-B active pocket. Cbl-b-IN-29 induces Jurkat cell release IL-2 with an EC50 of 159 nM, effectively inhibiting the function of immune E3 ubiquitin ligase. Cbl-b-IN-29 demonstrates robust anti-tumor efficacy in vivo with good tolerability and no observed adverse reactions. Cbl-b-IN-29 can be used for cancer immunotherapy, colorectal cancer and immune-oncology combination research.
-
BRD9 Degrader-2
0 ImagesCat. No.: HY-163809CAS No.: 3033018-68-4BRD9 Degrader-2 is a selective BRD9 molecular glue degrader. BRD9 Degrader-2 consists of a BRD9-binding ligand, a linker, and a warhead that promotes proteasomal degradation of BRD9 via a non-canonical PROTAC mechanism independent of CRBN or VHL E3 ligases. BRD9 Degrader-2 can be used in cancer research, including studies of malignant rhabdoid tumors, specific sarcomas, and acute myeloid leukemia.
-
Cbl-b-IN-8
0 ImagesCat. No.: HY-156764CAS No.: 2815223-33-5Cbl-b-IN-8 (Compound 293) is a casitas B-lineage lymphoma-b (Cbl-b) and c-Cbl inhibitor with IC50s of 5.5 nM and 7.8 nM, respectively.
-
Cbl-b-IN-11
0 ImagesCat. No.: HY-156767CAS No.: 2815225-15-9Cbl-b-IN-11 (Compound 466) is a casitas B-lineage lymphoma-b (Cbl-b) and c-Cbl inhibitor with IC50s of 6.4 nM and 6.1 nM, respectively.
-
DCN1 modulator-1
0 ImagesCat. No.: HY-184536CAS No.: 3085130-99-7DCN1 modulator-1 is a DCN1 modulator. DCN1 modulator-1 binds covalently to DCN2. DCN1 modulator-1 induces the expression of fetal hemoglobin mRNA (HBG1) and fetal hemoglobin protein (HbF). DCN1 modulator-1 is applicable to research related to sickle cell disease and thalassemia.
-
CP2-CPP
0 ImagesCat. No.: HY-P11792CP2-CPP is a conjugate of p27 Analogue CP2 (HY-P11020) and Antennapedia Peptide (HY-P0307). CP2-CPP crosses cell membranes and localizes to live cell cytosol. CP2-CPP blocks SCFSkp2/Cks1-p27 interaction to inhibit p27 ubiquitination and degradation, restoring p27 levels and inhibiting cell proliferation. CP2-CPP can be used for the research of cancer, such as breast cancer.
-
BRD4 degrader-2
0 ImagesCat. No.: HY-163639CAS No.: 3036530-43-2
-
AR Degrader-1
0 ImagesCat. No.: HY-163641AR Degrader-1 is a molecular glue degrader targeting the androgen receptor (AR). AR Degrader-1 induces androgen receptor degradation by recruiting the DCAF16 E3 ligase substrate receptor, thereby triggering ubiquitination and proteasomal degradation. AR Degrader-1 exhibits relatively selective degradation of the androgen receptor in prostate cancer cells, reducing the levels of only a small number of other proteins. AR Degrader-1 can be used in studies related to prostate cancer.
